Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators.
Oliver E AminEmily J ColbeckStephane DaffisShahzada KhanDhivya RamakrishnanDivya PattabiramanRuth ChuHolly Micolochick SteuerSophie LeharLeanne PeiserAdam PalazzoChristian FreyJessica DaviesHassan JavanbakhtWilliam M C RosenbergSimon P FletcherMala K MainiLaura J PallettPublished in: Hepatology (Baltimore, Md.) (2021)
GS-9688 induces cytokines in human peripheral blood mononuclear cells that are able to activate antiviral effector function by multiple immune mediators (HBV-specific CD8+ T cells, CD4+ follicular helper T cells, NK cells, and mucosal-associated invariant T cells). Although reducing the frequency of some immunoregulatory subsets, it enhances the immunosuppressive potential of others, highlighting potential biomarkers and immunotherapeutic targets to optimize the antiviral efficacy of GS-9688.